We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa
News

Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa

Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa
News

Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Under the agreement, Gentronix will conduct genotoxicity screening of compounds for Kowa for use in selected undisclosed therapeutic products in its development pipeline. Currently over 100 pharmaceutical and fine chemical companies in 17 countries have used the Gentronix proprietary GreenScreen HC assay technology as part of their genotoxicity profiling strategy.

“Gentronix is delighted to be working with Kowa in the Japanese market. We believe that the Gentronix GreenScreen assay with its outstanding specificity, high sensitivity and low compound requirement, is an ideal assay, as an early screen, to assist medicinal chemists make high quality compound decisions, improve attrition rates and avoid the late stage failure of drug candidates.” (John Nicholson, Gentronix CEO)

Advertisement